Translational and Clinical Comparison of Whole Genome and Transcriptome to Panel Sequencing in Precision Oncology
Cancer treatment has entered a new era where molecular insights are crucial for treatment decisions. Our study examined whether the sequencing method significantly affects therapy recommendations and implementations for patients with rare or advanced tumors.
MicroRNA dynamics, PTEN/PI3K/AKT signaling, and their relationship to breast cancer: prospects for pharmaceuticals and natural product application
Breast Cancer, PI3K/PTEN/AKT signaling pathway, microRNAs, Natural Products, Potential drugs.
Network topology controls the fate of cells during development and disease
This study explores how cells decide their future states through genetic networks. By analyzing their structure, we uncovered principles that govern cell diversity and decision-making. These insights enhance our understanding of development, disease, and potential therapeutic strategies.
Linking tissue injury to neural precursor reprogramming in gliomagenesis
In this article, we provide a behind-the-scenes narrative of a new publication from my lab, led by Akram Hamed, published today in Nature: Gliomagenesis mimics an injury response orchestrated by neural crest-like cells. https://www.nature.com/articles/s41586-024-08356-2
Towards Sustainable Benchmarking in AI for Digital Pathology
Deep Learning (DL) can transform medical diagnostics, but its environmental cost is often overlooked. A new benchmarking approach for DL in pathology is vital, integrating carbon footprint with diagnostic performance to develop sustainable, efficient AI solutions.
Concurrent DNA hypomethylation and epigenomic reprogramming driven by androgen receptor binding in bladder cancer oncogenesis
CUT&Tag sequencing reveals how the androgen receptor (AR) drives tumor heterogeneity and gender disparities in bladder cancer through epigenetic reprogramming.
The LEANORA study: Understanding the pharmacokinetics and pharmacogenomics of ribociclib in Black women
This study examined ribociclib pharmacokinetics and pharmacogenomics in 14 Black women with advanced breast cancer. The LEANORA study (NCT04657679) revealed that the ribociclib exposure and toxicity profile were similar between intermediate/normal and poor CYP3A5 metabolizers.
